Characterizing & Understanding Uncertainties

Paul Seligman, M.D., M.P.H. Executive Director, U.S. Regulatory Policy Amgen Inc.

May 12, 2014

IOMWorkshop on Characterizing and Communicating Uncertainty in the Assessment of Benefits and Risks of Pharmaceutical Products



Decision-making Approaches

Expert elicitation

- formal, scientific basis for "using judgment to supplement standard statistical tests"
- how to incorporate informal evidence that informs an expert's judgment alongside formal evidence

Bayesian statistical methods

 use of sensitivity analysis to test how assumptions about the prior distribution affect the posterior inference



Regulatory Decision-making Applying Analytic Techniques

- Scientific basis for eliciting and incorporating stakeholder preferences
 - forecasting consequences, uncertainties, thresholds, "tipping points"
- Sensitivity analysis
 - constructed preferences around different levels of uncertainty
 - for point estimates
 - across a range of attributes

INSTITUTE OF MEDICINE

OF THE NATIONAL ACADEMIES

Need for Regulatory Science

- Innovative Medicines Initiative (IMI) PROTECT*
 - Public-private consortium coordinated by the European Medicines Agency (EMA)
 - commitment to methods development
 - 47 studies, 13 pilot programs
 - Metric indicies
 - Estimation techniques
 - Utility survey techniques
- To date, little broad interest in US
- * Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium <u>www.imi-protect.eu</u>

INSTITUTE OF MEDICINE

OF THE NATIONAL ACADEMIES

Segment Two: Characterizing and Understanding Uncertainties

Discussion Questions

- Discuss analytical methods that hold promise for characterizing and incorporating uncertainty in the assessment of benefit and risk.
- What steps should the regulatory and research communities take to advance the methods and applicability of these tools?

INSTITUTE OF MEDICINE